Experts discuss the phase III SIERRA trial, which recently demonstrated durable complete responses in patients with acute myeloid leukemia<br />
Case 1: Primary Induction Failure (PIF)
Case 2: Early Relapse with Remission <6 months
Disease State of AML
SIERRA Trial Design
Hematopoietic
Hillard M. Lazarus, MD, FACP - Case Western Reserve University
Rajneesh Nath, MD - Banner MD Anderson Cancer Center Clinic
Alexander E. Perl, MD, MS - Hospital of the University of Pennsylvania
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More